Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...

The stock's fall snapped a two-day winning streak.

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...

Saudi Arabia’s Ministry of Industry and Mineral Resources signed a memorandum of understanding (MoU) with US-based Vertex ...

Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle ...

US biopharma Vertex Pharmaceuticals has previously presented positive Phase III data on suzetrigine, an investigational, oral ...

Vertex Pharmaceuticals (VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on ...